Literature DB >> 1911455

Home treatment of febrile neutropenia: an empirical oral antibiotic regimen.

M Gardembas-Pain1, B Desablens, L Sensebe, T Lamy, C Ghandour, M Boasson.   

Abstract

Between May 1988 and November 1989, 68 consecutive febrile courses supervening after polychemotherapy for lymphoma outpatients (median age 50 years) were treated by the combination of oral Pefloxacin/Amoxicillin Clavulanic acid. In terms of median data, neutropenia appeared on d9 [d1-d17], and lasted 5 days [2-9] with a PMN nadir observed at 0.104 x 10(9) [0-0.5 x 10(9)/l], while fever rose on d10 [1-24]. In 59 cases (87%), fever and/or focal symptoms disappeared within 3 days, after which treatment was maintained for 7 days. Nine failures were observed, of which 2 were due to abandonment of treatment, 2 to vomiting and 5 to persistence of the original symptoms. Meti Susceptible-Staphylococci were found in blood samples from 2 patients, one of whom, with grade IV lymphoma that had proved resistant to chemotherapy, died. The treatment was found to be effective and well tolerated, offering a good alternative to hospitalization during a transient chemotherapy-induced neutropenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911455     DOI: 10.1093/oxfordjournals.annonc.a057996

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

Authors:  James A Talcott; Beow Y Yeap; Jack A Clark; Robert D Siegel; Elizabeth Trice Loggers; Charles Lu; Paul A Godley
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.

Authors:  Ann M Hendricks; Elizabeth Trice Loggers; James A Talcott
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

3.  Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.

Authors:  J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 4.  Outpatient therapy for febrile neutropenia: clinical and economic implications.

Authors:  Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours.

Authors:  M Nobbenhuis; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 6.  Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients.

Authors:  C P Escalante; E B Rubenstein; K V Rolston
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

Review 7.  Empirical therapy for bacterial infections in neutropenic patients.

Authors:  J Klastersky
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

Review 8.  Infections in neutropenic patients. II: Management.

Authors:  P Engervall; M Björkholm
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

Review 9.  [Febrile neutropenia: practical aspects].

Authors:  P Harten; B Seyfarth; N Schmitz
Journal:  Med Klin (Munich)       Date:  1998-10-15

10.  A circadian distribution to febrile episodes in neutropenic patients.

Authors:  J Maher; P Browne; L Daly; S R McCann; P A Daly
Journal:  Support Care Cancer       Date:  1993-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.